查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1585643

生技藥品開發與受託製造廠商市場：按類型、產品類型、適應症、服務類型、最終用戶 - 2025-2030 年全球預測

Biologics Contract Development & Manufacturing Organization Market by Type (Mammalian, Non-mammalian), Product Type (Biologics, Biosimilars), Disease Indication, Service Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年生技藥品開發和受託製造廠商市場價值為98.8億美元，預計到2024年將達到105.9億美元，複合年成長率為7.44%，到2030年將達到16.3億美元。

生技藥品開發和受託製造廠商市場在生物製藥行業中發揮著至關重要的作用，提供細胞培養開發、生產流程和分析測試等基本服務。對生技藥品CDMO 的需求源於向不具備內部能力的製藥公司提供專業資源和專業知識的能力。該市場提供與單株抗體、疫苗、重組蛋白和基因治療相關的應用，涵蓋癌症、感染疾病和慢性病等廣泛的治療領域。從大型製藥公司到小型生物技術新興企業的最終用途提供者都利用 CDMO 的能力來加速藥物開發並更快地將產品推向市場。

主要市場統計
基準年[2023] 98.8億美元
預測年份 [2024] 105.9億美元
預測年份 [2030] 163.5億美元
複合年成長率（%） 7.44%

主要成長動力包括生技藥品因其在治療複雜疾病方面的精確性和有效性而不斷成長的需求、生物加工技術的進步以及降低營運成本和加強對核心能力的關注的外包趨勢，例如，生物製劑的增加。最近的機會在於個人化醫療，它使 CDMO 能夠進入快速成長的客製化治療領域，以及採用一次性技術，從而提供生產的靈活性和成本效率。公司可以透過投資先進的生物加工技術並擴大其服務範圍以包括整合開發解決方案來利用這些趨勢。

然而，挑戰仍然存在，例如嚴格的監管要求，這可能導致高昂的合規成本和緩慢的上市時間。由於生技藥品生產需求快速成長而出現的產能瓶頸也限制了市場成長，並可能影響生產計畫。創新和研究應著重於透過提高製造的可擴展性和效率（例如連續生物加工技術的開發）來解決這些限制。此外，您可以透過改善與技術開發人員的協作以及投資數位轉型（例如資料分析和人工智慧主導的見解）來推動業務成長。雖然這個市場本​​質上是競爭性的，但也有很大的合作潛力，需要平衡策略夥伴關係和創新以保持競爭力。

市場動態：快速發展的生技藥品合約開發和受託製造廠商市場的關鍵市場洞察

供需的動態交互作用正在改變生技藥品開發和受託製造廠商市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 對標靶治療的細胞和基因治療的需求不斷成長
    • 在上游和下游加工中更多地採用一次性技術
    • 人們越來越關注新的生物治療藥物的開發
  • 市場限制因素
    • 對製造生技藥品相關的產品品質和高成本的擔憂
  • 市場機會
    • 透過生物製程技術的進步實現高效的大規模生產
    • 擴大研發創新投入，增加生技藥品臨床試驗數量
  • 市場問題
    • 政府對 CDMO 組織的嚴格監管

波特的五力：駕馭生技藥品開發和受託製造廠商市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解生技藥品開發和受託製造廠商市場的外部影響

外部宏觀環境因素在塑造生技藥品開發和受託製造廠商市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解生技藥品開發/受託製造廠商市場的競爭狀況

對生技藥品開發和受託製造廠商市場的詳細市場佔有率分析提供了對供應商績效的全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣生技藥品開發與受託製造廠商市場供應商的績效評估

FPNV 定位矩陣是評估生技藥品開發和受託製造廠商市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：在生技藥品開發和受託製造廠商市場中製定成功之路

對於旨在加強其在全球市場的影響力的公司來說，對生技藥品開發和受託製造廠商市場進行策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 對標靶治療的細胞和基因治療的需求不斷增加
      • 在上游和下游加工中更多地採用一次性技術
      • 越來越關注新型生物製藥的開發
    • 抑制因素
      • 對生物製藥製造相關產品品質和高成本的擔憂
    • 機會
      • 生物加工技術的進步使高效的大規模生產成為可能。
      • 增加對研究和創新的投資並增加生技藥品的臨床測試
    • 任務
      • 針對 CDMO 組織的嚴格政府法規
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章生技藥品開發與受託製造廠商市場：按類型

  • 介紹
  • 哺乳動物的
  • 非哺乳動物

第7章生技藥品開發與受託製造廠商市場：依產品類型

  • 介紹
  • 生技藥品
    • 反義和分子治療
    • 單複製
    • 重組蛋白
    • 疫苗
  • 生物相似藥

第8章生技藥品開發/受託製造廠商市場：依適應症分類

  • 介紹
  • 心血管疾病
  • 血液疾病
  • 免疫疾病
  • 腫瘤學

第9章生技藥品開發和受託製造廠商市場：按服務類型

  • 介紹
  • 細胞株開發
    • 哺乳動物的
    • 微生物
  • 製程開發
    • 下游
      • 雜質、分離、鑑定
      • 藥物分析
      • 理化表徵
    • 上游
      • 哺乳動物的
      • 微生物

第 10 章生技藥品開發和受託製造廠商市場：按最終用戶分類

  • 介紹
  • 生物製藥公司
  • 研究所

第11章 北美和南美生技藥品開發和受託製造廠商市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太生技藥品受託製造廠商市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲生技藥品開發和受託製造廠商市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 三星生物製品擴大生物相似藥 CDMO 產能
    • Catalent 擴展生物製劑服務平台
    • 旭化成集團美國生物製藥 CDMO Bionova Scientific 擴大生產能力
  • 戰略分析和建議

公司名單

  • AbbVie, Inc.
  • Abzena Ltd.
  • Aenova Holding GmbH
  • AGC Biologics GmbH
  • Avid Bioservices, Inc.
  • Binex Co. Limited
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Emergent BioSolutions, Inc.
  • Fujifilm Holdings Corporation
  • Icon PLC
  • JSR Life Sciences, LLC
  • Lonza Group AG
  • Parexel International Corporation
  • ProBioGen AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Takeda Pharmaceutical Company Limited
  • Thermo Fisher Scientific, Inc.
  • Toyobo Co., Ltd.
  • WuXi Biologics Inc.
Product Code: MRR-957C47F9527F

The Biologics Contract Development & Manufacturing Organization Market was valued at USD 9.88 billion in 2023, expected to reach USD 10.59 billion in 2024, and is projected to grow at a CAGR of 7.44%, to USD 16.35 billion by 2030.

The Biologics Contract Development and Manufacturing Organization (CDMO) market is pivotal in the biopharmaceutical industry, providing essential services such as cell culture development, production processes, and analytical testing. The necessity of biologics CDMOs arises from their ability to offer specialized resources and expertise to pharmaceutical companies, which may lack in-house capabilities. This market serves applications related to monoclonal antibodies, vaccines, recombinant proteins, and gene therapies, catering to a wide array of therapeutic areas including oncology, infectious diseases, and chronic conditions. End-use providers range from large pharmaceutical firms to small biotech startups, leveraging CDMO capabilities to accelerate drug development and bring products to market faster.

KEY MARKET STATISTICS
Base Year [2023] USD 9.88 billion
Estimated Year [2024] USD 10.59 billion
Forecast Year [2030] USD 16.35 billion
CAGR (%) 7.44%

Key growth drivers include the escalating demand for biologics due to their precision and efficacy in treating complex diseases, technological advancements in bioprocessing, and the increasing trend towards outsourcing to reduce operational costs and enhance focus on core competencies. Recent opportunities lie in personalized medicine, where CDMOs can tap into the burgeoning field of tailored therapies, and in the adoption of single-use technology, which offers flexibility and cost-effectiveness in production. Companies could capitalize on these trends by investing in advanced bioprocessing technologies and expanding service offerings to include integrated development solutions.

However, challenges persist, such as stringent regulatory requirements, which necessitate high compliance costs and can delay time-to-market. Market growth is also constrained by capacity bottlenecks stemming from the rapid increase in biologics production demand, which can impact production timelines. Innovation and research should focus on addressing these limitations by enhancing manufacturing scalability and efficiency, such as through the development of continuous bioprocessing technologies. Additionally, improving collaborations with technology developers and investing in digital transformations like data analytics and AI-driven insights can foster business growth. The nature of this market is competitive yet ripe with collaboration potential, necessitating a balance between strategic partnership and technological innovation to maintain a competitive edge.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Biologics Contract Development & Manufacturing Organization Market

The Biologics Contract Development & Manufacturing Organization Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising demand for cell and gene therapies for targeted treatment
    • Growing adoption of single-use technologies in upstream and downstream processing
    • Increasing focus on developing novel biotherapeutics
  • Market Restraints
    • Concern regarding product quality and high costs associated with biologics products manufacturing
  • Market Opportunities
    • Advancement in bioprocessing technologies enabled efficient large-scale production
    • Growing investment in research and innovation and rising numbers of clinical trials for biologics
  • Market Challenges
    • Strict governmental laws and regulations for CDMO organizations

Porter's Five Forces: A Strategic Tool for Navigating the Biologics Contract Development & Manufacturing Organization Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Biologics Contract Development & Manufacturing Organization Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Biologics Contract Development & Manufacturing Organization Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Biologics Contract Development & Manufacturing Organization Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Biologics Contract Development & Manufacturing Organization Market

A detailed market share analysis in the Biologics Contract Development & Manufacturing Organization Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Biologics Contract Development & Manufacturing Organization Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Biologics Contract Development & Manufacturing Organization Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Biologics Contract Development & Manufacturing Organization Market

A strategic analysis of the Biologics Contract Development & Manufacturing Organization Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Biologics Contract Development & Manufacturing Organization Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Abzena Ltd., Aenova Holding GmbH, AGC Biologics GmbH, Avid Bioservices, Inc., Binex Co. Limited, Boehringer Ingelheim International GmbH, Cambrex Corporation, Catalent, Inc., Emergent BioSolutions, Inc., Fujifilm Holdings Corporation, Icon PLC, JSR Life Sciences, LLC, Lonza Group AG, Parexel International Corporation, ProBioGen AG, Recipharm AB, Rentschler Biopharma SE, Samsung Biologics, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Inc., Toyobo Co., Ltd., and WuXi Biologics Inc..

Market Segmentation & Coverage

This research report categorizes the Biologics Contract Development & Manufacturing Organization Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Mammalian and Non-mammalian.
  • Based on Product Type, market is studied across Biologics and Biosimilars. The Biologics is further studied across Antisense & Molecular Therapy, Monoclonal, Recombinant Proteins, and Vaccines.
  • Based on Disease Indication, market is studied across Cardiovascular Disorders, Hematological Disorders, Immunological Disorders, and Oncology.
  • Based on Service Type, market is studied across Cell Line Development and Process Development. The Cell Line Development is further studied across Mammalian and Microbial. The Process Development is further studied across Downstream and Upstream. The Downstream is further studied across Impurity, Isolation, & Identification, Pharmaceutical Analysis, and Physicochemical Characterization. The Upstream is further studied across Mammalian and Microbial.
  • Based on End-User, market is studied across Biopharmaceutical Companies and Research Laboratories.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising demand for cell and gene therapies for targeted treatment
      • 5.1.1.2. Growing adoption of single-use technologies in upstream and downstream processing
      • 5.1.1.3. Increasing focus on developing novel biotherapeutics
    • 5.1.2. Restraints
      • 5.1.2.1. Concern regarding product quality and high costs associated with biologics products manufacturing
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancement in bioprocessing technologies enabled efficient large-scale production
      • 5.1.3.2. Growing investment in research and innovation and rising numbers of clinical trials for biologics
    • 5.1.4. Challenges
      • 5.1.4.1. Strict governmental laws and regulations for CDMO organizations
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Biologics Contract Development & Manufacturing Organization Market, by Type

  • 6.1. Introduction
  • 6.2. Mammalian
  • 6.3. Non-mammalian

7. Biologics Contract Development & Manufacturing Organization Market, by Product Type

  • 7.1. Introduction
  • 7.2. Biologics
    • 7.2.1. Antisense & Molecular Therapy
    • 7.2.2. Monoclonal
    • 7.2.3. Recombinant Proteins
    • 7.2.4. Vaccines
  • 7.3. Biosimilars

8. Biologics Contract Development & Manufacturing Organization Market, by Disease Indication

  • 8.1. Introduction
  • 8.2. Cardiovascular Disorders
  • 8.3. Hematological Disorders
  • 8.4. Immunological Disorders
  • 8.5. Oncology

9. Biologics Contract Development & Manufacturing Organization Market, by Service Type

  • 9.1. Introduction
  • 9.2. Cell Line Development
    • 9.2.1. Mammalian
    • 9.2.2. Microbial
  • 9.3. Process Development
    • 9.3.1. Downstream
      • 9.3.1.1. Impurity, Isolation, & Identification
      • 9.3.1.2. Pharmaceutical Analysis
      • 9.3.1.3. Physicochemical Characterization
    • 9.3.2. Upstream
      • 9.3.2.1. Mammalian
      • 9.3.2.2. Microbial

10. Biologics Contract Development & Manufacturing Organization Market, by End-User

  • 10.1. Introduction
  • 10.2. Biopharmaceutical Companies
  • 10.3. Research Laboratories

11. Americas Biologics Contract Development & Manufacturing Organization Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Biologics Contract Development & Manufacturing Organization Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Biologics Contract Development & Manufacturing Organization Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Biosimilar CDMO Capacity Increased in Samsung Biologics
    • 14.3.2. Catalent expands its biologics services platform
    • 14.3.3. Bionova Scientific, U.S. biologics CDMO of the Asahi Kasei Group, expands manufacturing capacity
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie, Inc.
  • 2. Abzena Ltd.
  • 3. Aenova Holding GmbH
  • 4. AGC Biologics GmbH
  • 5. Avid Bioservices, Inc.
  • 6. Binex Co. Limited
  • 7. Boehringer Ingelheim International GmbH
  • 8. Cambrex Corporation
  • 9. Catalent, Inc.
  • 10. Emergent BioSolutions, Inc.
  • 11. Fujifilm Holdings Corporation
  • 12. Icon PLC
  • 13. JSR Life Sciences, LLC
  • 14. Lonza Group AG
  • 15. Parexel International Corporation
  • 16. ProBioGen AG
  • 17. Recipharm AB
  • 18. Rentschler Biopharma SE
  • 19. Samsung Biologics
  • 20. Takeda Pharmaceutical Company Limited
  • 21. Thermo Fisher Scientific, Inc.
  • 22. Toyobo Co., Ltd.
  • 23. WuXi Biologics Inc.

LIST OF FIGURES

  • FIGURE 1. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET RESEARCH PROCESS
  • FIGURE 2. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NON-MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ANTISENSE & MOLECULAR THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MONOCLONAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMPURITY, ISOLATION, & IDENTIFICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHARMACEUTICAL ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHYSICOCHEMICAL CHARACTERIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 142. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 143. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 151. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 152. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 153. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 158. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 161. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 162. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 163. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 168. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 171. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 172. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 173. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 175. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 178. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 181. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 182. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 183. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 188. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 191. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 192. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 193. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 195. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 198. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 199. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 205. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 208. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 211. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 212. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 213. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 215. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 218. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 221. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 222. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 223. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 225. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 228. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 229. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 231. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 232. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 233. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UPSTREAM, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DISEASE INDICATION, 2018-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CELL LINE DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PROCESS DEVELOPMENT, 2018-2030 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DOWNSTREAM, 2018-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY UP